HomeTMOF • VIE
add
Thermo Fisher Scientific Inc
Nakaraang pagsara
€494.60
Sakop ng araw
€483.55 - €492.30
Sakop ng taon
€338.30 - €585.40
Market cap
213.27B USD
Average na Volume
18.00
P/E ratio
-
Dividend yield
-
Primary exchange
NYSE
Sa balita
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Set 2025info | Y/Y na pagbabago |
|---|---|---|
Kita | 11.12B | 4.94% |
Gastos sa pagpapatakbo | 2.45B | 0.99% |
Net na kita | 1.62B | -0.86% |
Net profit margin | 14.53 | -5.53% |
Kita sa bawat share | 5.79 | 9.66% |
EBITDA | 2.82B | 5.75% |
Aktuwal na % ng binabayarang buwis | 11.32% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Set 2025info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 3.55B | -46.64% |
Kabuuang asset | 103.02B | 2.65% |
Kabuuang sagutin | 51.87B | 1.17% |
Kabuuang equity | 51.15B | — |
Natitirang share | 375.71M | — |
Presyo para makapag-book | 3.64 | — |
Return on assets | 5.25% | — |
Return on capital | 6.21% | — |
Cash Flow
Net change in cash
| (USD) | Set 2025info | Y/Y na pagbabago |
|---|---|---|
Net na kita | 1.62B | -0.86% |
Cash mula sa mga operasyon | 2.24B | 3.37% |
Cash mula sa pag-invest | -4.12B | -15.23% |
Cash mula sa financing | -632.00M | 46.89% |
Net change in cash | -2.59B | -6.80% |
Malayang cash flow | 1.47B | -21.49% |
Tungkol
Thermo Fisher Scientific Inc. is an American life science and clinical research company. It is a global supplier of analytical instruments, clinical development solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services. Based in Waltham, Massachusetts, Thermo Fisher was formed through the merger of Thermo Electron and Fisher Scientific in 2006. Thermo Fisher Scientific has acquired other reagent, consumable, instrumentation, and service providers, including Life Technologies Corporation, Alfa Aesar, Affymetrix, FEI Company, BD Advanced Bioprocessing, and PPD.
It ranked 104th on the Fortune 500 list based on its 2024 annual revenue of $42.879 billion.
Thermo Fisher announced a $2 billion investment over four years in the U.S., including $1.5 billion for expanding manufacturing capacity and $500 million for R&D investment. This initiative aims to bolster domestic biotech manufacturing, create high-paying jobs, and reinforce the U.S. healthcare supply chain. Wikipedia
Itinatag
1956
Headquarters
Website
Mga Empleyado
125,000
